How do you think the new GigE standards will influence the machine vision industry?
Respond or ask your question now!
ART Advanced Research Technologies (ART), a Canadian medical device company and a provider of optical molecular imaging products for the healthcare and pharmaceutical industries, will participate in the Biomedical Optics Meeting of the Optical Society of America (OSA BIOMED), March 19-22, in Fort Lauderdale, Fla.
At the OSA BIOMED meeting, results obtained from ART's eXplore Optix system will be featured in the Poster Session III, to be held on Tuesday, March 21 at 6 p.m. Dr. Guobin Ma, Senior Scientist at ART, will present a poster entitled "Comparison of Simplified Monte Carlo Simulation and Diffusion Approximation for Fluorescent Signal from Phantoms with Typical Mouse Optical Properties." Researchers computed fluorescent signals from mouse-tissue like phantoms using both Monte Carlo simulation and diffusion approximation. Comparison studies between the Monte-Carlo method and the diffusion equation show an equivalency in the two methods for depths greater than 3 mm. A second poster, entitled "Sensitivity Characterization of a Time-Domain Fluorescence Imager: eXplore Optix," will also be presented by Dr. Guobin Ma. Using tissue-like phantoms it was possible to precisely characterize the sensitivity of ART's eXplore Optix system with Cy5.5.
In addition, preliminary results from ongoing clinical studies are described in a poster entitled "SoftScan Optical Breast Imaging System: Clinical Results." The overall results, to be presented by Zahia Ichalalene, Electro-Optical Research Scientist at ART, demonstrate SoftScan's ability to quantify optical and physiological breast tissue properties. Analysis of the clinical data shows that the system can discriminate between normal and diseased tissues using specific optical and physiological signatures.
"In the rapidly progressing field of optics applied to medicine, the OSA BIOMED meeting will provide an important venue to present the latest information on ART research using its patented time-domain optical molecular imaging technology," said Mario Khayat, ART's VP, Optical Products. "Indeed, molecular imaging - and specifically optical imaging - will deliver countless applications from the lab bench to the bedside, and ART's technology platform is well-positioned in this emerging field," added Khayat.
ART is also a sponsor and exhibitor of the meeting, which brings together scientists, engineers and physicians engaged in research using optical methods in biology and medicine.